Innovative & Next Generation Biotechnology!
A Korean company.
NGeneBio was founded in October 2015 as a joint venture between Genecurix and Korea Telecom, develops in vitro diagnostics (IVD) / companion diagnostics (CDx) products and bioinformatics software with cutting-of-edge technologies including next generation sequencing (NGS).
The company launched NGS-based hereditary breast / ovarian cancer panel (BRCAaccuTest™) with clinical analysis S/W (NGeneAnalysis™) and received CE-IVD mark in Jun/2017. NGeneBio covers cancer in vitro diagnosis and companion diagnosis, bioinformatics system, disease diagnosis, liquid biopsy.
NGeneBio is specialized in developing NGS panels, NGS Analysis softwares, Sequencing-Genetic profiling, & qPCR COVID-19 assay.
